Arena Pharmaceuticals Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arena Pharmaceuticals stock.
View analyst ratings for Arena Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Arena Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arena Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Arena Pharmaceuticals.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its earnings results on Monday, February, 22nd. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the Zacks' consensus estimate of ($1.85) by $0.25. During the same period in the previous year, the company earned ($1.76) earnings per share.
View Arena Pharmaceuticals' earnings history.

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARNA shares have increased by 82.0% and is now trading at $73.57.
View which stocks have been most impacted by COVID-19.

Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

15 brokerages have issued 1 year price targets for Arena Pharmaceuticals' shares. Their forecasts range from $62.00 to $120.00. On average, they expect Arena Pharmaceuticals' stock price to reach $89.80 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price.
View analysts' price targets for Arena Pharmaceuticals or view top-rated stocks among Wall Street analysts.

16 employees have rated Arena Pharmaceuticals CEO Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among Arena Pharmaceuticals' employees.

Some companies that are related to Arena Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
View all of ARNA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), (CGC), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Arena Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.27%), Avoro Capital Advisors LLC (7.20%), Lord Abbett & CO. LLC (3.18%), Northern Trust Corp (1.67%), Alliancebernstein L.P. (1.67%) and Bank of New York Mellon Corp (1.55%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Kevin Robert Lind, Manmeet Singh Soni, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz.
View institutional ownership trends for Arena Pharmaceuticals.

ARNA stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Rhenman & Partners Asset Management AB, Wells Fargo & Company MN, Panagora Asset Management Inc., Dimensional Fund Advisors LP, Nuveen Asset Management LLC, Alliancebernstein L.P., and Rothschild & Co. Asset Management US Inc.. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Manmeet Singh Soni, Robert Lisicki, Tina Susan Nova, and Vincent Aurentz.
View insider buying and selling activity for Arena Pharmaceuticals or view top insider-selling stocks.

ARNA stock was purchased by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, Norges Bank, Avidity Partners Management LP, SummerHaven Investment Management LLC, Viking Global Investors LP, Credit Suisse AG, Rice Hall James & Associates LLC, and Nicholas Investment Partners LP.
View insider buying and selling activity for Arena Pharmaceuticals or or view top insider-buying stocks.

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARNA stock can currently be purchased for approximately $73.57.

Arena Pharmaceuticals has a market capitalization of $4.44 billion and generates $806.43 million in revenue each year. The biopharmaceutical company earns $397.55 million in net income (profit) each year or $7.69 on an earnings per share basis.

Arena Pharmaceuticals employs 320 workers across the globe.

The official website for Arena Pharmaceuticals is www.arenapharm.com.

Arena Pharmaceuticals is headquartered at 6154 Nancy Ridge Drive, San Diego CA, 92121.

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]